[go: up one dir, main page]

DK0670162T3 - Farmaceutiske formuleringer indeholdende raloxifen, et overfladeaktivt middel og et vandopløseligt fortyndingsmiddel - Google Patents

Farmaceutiske formuleringer indeholdende raloxifen, et overfladeaktivt middel og et vandopløseligt fortyndingsmiddel

Info

Publication number
DK0670162T3
DK0670162T3 DK95301291T DK95301291T DK0670162T3 DK 0670162 T3 DK0670162 T3 DK 0670162T3 DK 95301291 T DK95301291 T DK 95301291T DK 95301291 T DK95301291 T DK 95301291T DK 0670162 T3 DK0670162 T3 DK 0670162T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical formulations
surfactant
water
formulations containing
soluble diluent
Prior art date
Application number
DK95301291T
Other languages
English (en)
Inventor
Arvind Lavji Thakkar
Stephanie Ann Sweetana
Lowell Lee Gibson
Kerry John Hartauer
Julian Larry Stowers
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0670162T3 publication Critical patent/DK0670162T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK95301291T 1994-03-02 1995-02-28 Farmaceutiske formuleringer indeholdende raloxifen, et overfladeaktivt middel og et vandopløseligt fortyndingsmiddel DK0670162T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20491594A 1994-03-02 1994-03-02
SG1997000220A SG65636A1 (en) 1994-03-02 1997-01-30 Orally administrable pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DK0670162T3 true DK0670162T3 (da) 2002-03-11

Family

ID=26665140

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95301291T DK0670162T3 (da) 1994-03-02 1995-02-28 Farmaceutiske formuleringer indeholdende raloxifen, et overfladeaktivt middel og et vandopløseligt fortyndingsmiddel

Country Status (22)

Country Link
EP (1) EP0670162B1 (da)
JP (1) JP3574210B2 (da)
CN (1) CN1098684C (da)
AT (1) ATE211910T1 (da)
AU (1) AU684882B2 (da)
BR (1) BR9500758A (da)
CA (1) CA2143263C (da)
CZ (1) CZ286119B6 (da)
DE (1) DE69524981T2 (da)
DK (1) DK0670162T3 (da)
ES (1) ES2166799T3 (da)
FI (1) FI117042B (da)
HU (1) HU225418B1 (da)
IL (1) IL112746A (da)
NO (1) NO314286B1 (da)
NZ (1) NZ270588A (da)
PL (1) PL178858B1 (da)
PT (1) PT670162E (da)
RU (1) RU2118540C1 (da)
SG (1) SG65636A1 (da)
SI (1) SI0670162T1 (da)
ZA (1) ZA951497B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
PT910369E (pt) * 1996-03-26 2010-06-04 Lilly Co Eli Benzotiofenos, formulações que os contêm, e métodos
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
ZA979720B (en) 1996-10-30 1999-04-29 Lilly Co Eli Prophylaxis of breast cancer
IL122026A0 (en) * 1996-10-30 1998-03-10 Lilly Co Eli Improvements in or relating to the prophylaxis of breast cancer
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
JP4798924B2 (ja) * 1999-12-13 2011-10-19 中外製薬株式会社 ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物
CN1414941A (zh) 1999-12-13 2003-04-30 中外制药株式会社 具有羟羰基-卤代烷基侧链的化合物
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
WO2002085405A2 (en) * 2001-04-24 2002-10-31 Merck Patent Gmbh COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
EP1546138B1 (en) 2002-09-30 2012-01-18 A/S GEA Farmaceutisk Fabrik Raloxifene l-lactate or a hemihydrate thereof, their uses, pharmaceutical compositions and preparation processes
US20050008704A1 (en) * 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
DK2054042T3 (da) 2006-06-30 2020-08-03 Iceutica Pty Ltd Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
CA2696984C (en) * 2007-10-16 2013-04-23 Pharmathen S.A. Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
CL2008003799A1 (es) * 2007-12-21 2009-12-18 Synthon Bv Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
UA106231C2 (uk) 2009-04-24 2014-08-11 Айсьютика Пти Лтд Разова доза фармацевтичної композиції індометацину (варіанти)
WO2011000581A2 (en) 2009-07-02 2011-01-06 Synthon B.V. Raloxifene composition
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN103006570B (zh) * 2012-10-08 2013-12-25 孙维会 一种阿佐昔芬速释微丸及其制备方法
WO2014082651A1 (en) * 2012-11-30 2014-06-05 Pharmathen S.A. Novel method for improving the bioavailability of low aqueous solubility drugs
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
KR102612983B1 (ko) * 2016-09-30 2023-12-13 한미약품 주식회사 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
IL112746A (en) 1999-12-31
BR9500758A (pt) 1995-10-24
CA2143263A1 (en) 1995-09-03
EP0670162B1 (en) 2002-01-16
CZ286119B6 (cs) 2000-01-12
NO950799D0 (no) 1995-03-01
PT670162E (pt) 2002-06-28
DE69524981T2 (de) 2002-08-29
DE69524981D1 (de) 2002-02-21
HU225418B1 (en) 2006-11-28
IL112746A0 (en) 1995-05-26
ATE211910T1 (de) 2002-02-15
SI0670162T1 (en) 2002-06-30
AU684882B2 (en) 1998-01-08
PL307491A1 (en) 1995-09-04
EP0670162A1 (en) 1995-09-06
RU2118540C1 (ru) 1998-09-10
CA2143263C (en) 2002-01-08
CZ49995A3 (en) 1995-10-18
JPH07277973A (ja) 1995-10-24
NO314286B1 (no) 2003-03-03
HUT72661A (en) 1996-05-28
FI950947A0 (fi) 1995-03-01
ES2166799T3 (es) 2002-05-01
FI117042B (fi) 2006-05-31
AU1354895A (en) 1995-09-07
NO950799L (no) 1995-09-04
PL178858B1 (pl) 2000-06-30
FI950947L (fi) 1995-09-03
SG65636A1 (en) 1999-06-22
CN1112420A (zh) 1995-11-29
NZ270588A (en) 1996-01-26
ZA951497B (en) 1996-08-23
CN1098684C (zh) 2003-01-15
HU9500635D0 (en) 1995-04-28
JP3574210B2 (ja) 2004-10-06

Similar Documents

Publication Publication Date Title
DK0670162T3 (da) Farmaceutiske formuleringer indeholdende raloxifen, et overfladeaktivt middel og et vandopløseligt fortyndingsmiddel
DK0698393T3 (da) 3-/-menthoxypropan-1,2-diol som solubiliseringsmiddel og præparat til udvortes brug, der indeholder samme
ES2052809T3 (es) Agente desinfectante tuberculocida.
DK0425016T3 (da) Antimikrobiel fremgangsmåde og formulering med anvendelse af type II endoglycosidase og antimikrobielt middel
NO902280L (no) Ny poroes farmasoeytisk form og fremstilling derav.
NO950315L (no) Orale preparater
MA23136A1 (fr) Composition de nettoyage comprenant des tensio- actifs a courte chaine .
NO913035D0 (no) (2r)-2-(di(2-propyl)fosfonylmetoksy)-3-p-toluensulfonyloksy-1-trimetylacetoksypropan, fremgangsmaate for fremstilling og anvendelse derav.
NO902277L (no) Baere- eller foeringsvalse og anordning som anvender slike.
FI952540L (fi) Puhdistuskoostumukset, joissa on hyvin hydrofiilisiä ja hyvin hydrofobisia ei-ionisia pinta-aktiivisia aineita
ES2129108T3 (es) Procedimiento para una preparacion estabilizadora para lentes de contacto.
NO900564D0 (no) Overflateaktivt middel.
NO963113L (no) Farmasöytiske preparater omfattende hirudin
NO901169D0 (no) Azol-1-alkanamider som anti-arrytmiske midler og fremstilling derav.
EP0615695A3 (en) Sterilizer with reduced surface pollution.
ATE149360T1 (de) Zahnseide mit chemotherapeutischen wirkstoffen
MY117590A (en) Orally administerable pharmaceutical formulations
NO901200D0 (no) Azol-1-alkanamider som anti-arrytmiske midler og fremstilling derav.
DK0482213T3 (da) Antineoplastisk middel
IT9022245A0 (it) Composizioni e metodo per la disinfezione e la pulizia delle lenti a contatto rigide, semirigide e morbide.
IT8922281A0 (it) Composizioni e metodo per la disinfezione e la pulizia delle lenti a contatto rigide, semirigide e morbide.
IT8620095A0 (it) Apparecchiatura per sterilizzare lenti a contatto, in particolare lenti morbide.